The Cancer Research Institute (CRI) has selected the Immunology Quality Assurance Center (IQAC) to provide central lab services for the Cancer Vaccine Consortium's Immune Proficiency Panel Program. Monitoring the antigen-specific immune response has become an important end point in the clinical evaluation of specific cancer immunotherapeutics. The early identification of such responses allows prioritizing vaccines for further clinical evaluation. The Cancer Vaccine Consortium has established an ImmunoAssay Working Group to help facilitate and standardize the immune monitoring approaches in the larger cancer vaccine community. The program’s objectives are: 1) to offer an external validation program, and 2) to enhance assay harmonization.